Swiss National Bank boosted its position in Arvinas, Inc. (NASDAQ:ARVN) by 1.1% in the 1st quarter, HoldingsChannel.com reports. The firm owned 70,700 shares of the company’s stock after buying an additional 800 shares during the period. Swiss National Bank’s holdings in Arvinas were worth $4,673,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Credit Suisse AG boosted its stake in Arvinas by 101.3% in the 4th quarter. Credit Suisse AG now owns 33,821 shares of the company’s stock valued at $2,872,000 after purchasing an additional 17,017 shares during the period. State of New Jersey Common Pension Fund D bought a new stake in Arvinas in the 1st quarter valued at $1,958,000. Advisory Services Network LLC bought a new stake in shares of Arvinas during the 4th quarter valued at $95,000. Pura Vida Investments LLC bought a new stake in shares of Arvinas during the 4th quarter valued at $2,548,000. Finally, US Bancorp DE lifted its position in shares of Arvinas by 253.7% during the 1st quarter. US Bancorp DE now owns 520 shares of the company’s stock valued at $35,000 after acquiring an additional 373 shares during the period. Institutional investors and hedge funds own 88.13% of the company’s stock.
A number of analysts have recently weighed in on ARVN shares. Zacks Investment Research upgraded Arvinas from a “sell” rating to a “hold” rating in a research report on Friday, May 7th. Truist started coverage on Arvinas in a research report on Wednesday, April 21st. They set a “buy” rating and a $150.00 target price for the company. Northern Trust Capital Markets started coverage on Arvinas in a research report on Wednesday, April 21st. They set a “buy” rating for the company. Truist Securities started coverage on Arvinas in a research report on Wednesday, April 21st. They set a “buy” rating and a $150.00 target price for the company. Finally, UBS Group started coverage on Arvinas in a report on Thursday, May 20th. They set a “buy” rating and a $123.00 price target for the company. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $117.00.
Arvinas (NASDAQ:ARVN) last issued its earnings results on Monday, May 3rd. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.01). Arvinas had a negative return on equity of 33.38% and a negative net margin of 656.61%. On average, equities analysts anticipate that Arvinas, Inc. will post -3.45 earnings per share for the current year.
In other news, insider Ian Taylor sold 25,000 shares of the stock in a transaction dated Monday, April 5th. The stock was sold at an average price of $66.81, for a total value of $1,670,250.00. Following the completion of the sale, the insider now owns 103,645 shares of the company’s stock, valued at $6,924,522.45. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 10.99% of the company’s stock.
Arvinas, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer.
Featured Story: How much money do you need to begin day trading?
Want to see what other hedge funds are holding ARVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arvinas, Inc. (NASDAQ:ARVN).
Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.